| Hans-Günter Meyer-Thompson | Verschiedenes
USA. Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O™ to Treat Opioid Use Disorder reSET-O™ is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder
USA. Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O™ to Treat Opioid Use Disorder
reSET-O™ is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder
Pear Therapeutics is leading the development of a new therapeutic class with two FDA-authorized PDTs and a robust pipeline of therapeutics across disease areas
Sandoz will lead U.S. commercial launch, anticipated in coming days in Q4
As part of broader Novartis digital revolution, Sandoz aims to increase patient engagement and improve access to treatment through digital solutions. (Pear Therapeutics, 10.12.2018)